Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00794625 |
Recruitment Status : Unknown
Verified July 2012 by Joseph Blader, National Institute of Mental Health (NIMH).
Recruitment status was: Recruiting
First Posted : November 20, 2008
Last Update Posted : July 16, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Attention Deficit Disorder With Hyperactivity | Drug: Valproate Drug: Risperidone Drug: Placebo Drug: Stimulant medication Behavioral: Behavioral family counseling | Phase 4 |
Attention deficit with hyperactivity disorder (ADHD) is a common childhood mental disorder that affects 3% to 5% of all American children. Symptoms of ADHD commonly include inability to focus or exercise normal inhibition, and in some cases, aggressive behavior. Approximately 33% to 50% of children with ADHD develop oppositional defiant disorder (ODD), and about 20% to 40% develop a conduct disorder (CD). These disorders are characterized by defiant, belligerent, and otherwise aggressive behavior. Treatment for ADHD generally includes use of stimulant medications that decrease impulsivity and increase attentiveness, such as methylphenidate (Ritalin) or dextroamphetamine (Dexedrine), but these do not always affect aggression. To treat aggression in ADHD, many physicians prescribe additional medications, including the mood stabilizing medication valproate and the antipsychotic medication risperidone.
There is no clinical evidence proving that using multiple types of medications is safe and effective. This study will treat children with ADHD and aggression with a combination of stimulants and antipsychotic or mood stabilizing medications to determine whether the aggressive behaviors and ADHD symptoms are reduced without harmful side effects.
This study has two phases. During the first phase, which will last 3 to 6 weeks, participants will be treated with normal ADHD stimulant medications. During the second phase, those whose aggressive behavior is not effectively suppressed by stimulant medication alone will then be randomly assigned to also receive valproate, risperidone, or placebo for 8 weeks. After 8 weeks, children whose aggression persists will be switched from either valproate to risperidone or risperidone to valproate for another 8 weeks. Those on placebo will not switch medications. All participants will attend weekly monitoring visits for 11 to 16 weeks over the course of the study. At these visits, aggression levels and medication side effects will be assessed. Families will also meet with the researchers to discuss the child's progress and will attend behavioral counseling with a therapist.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 270 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Adjunctive Treatment With Divalproex or Risperidone for Aggression Refractory to Stimulant Monotherapy Among Children With ADHD |
Study Start Date : | November 2008 |
Estimated Primary Completion Date : | November 2012 |
Estimated Study Completion Date : | April 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: 1
During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add valproate and behavioral family counseling to their treatment during Phase 2. If they do not respond to valproate, they will be switched to risperidone.
|
Drug: Valproate
Standard therapeutic doses of valproate, set according to valproic acid blood level, for 8 weeks
Other Names:
Drug: Risperidone Standard therapeutic doses of risperidone for 8 weeks
Other Name: Risperdal Drug: Stimulant medication Stimulant medication standard in the care of ADHD, such as methylphenidate or dextroamphetamine
Other Names:
Behavioral: Behavioral family counseling Weekly behavioral counseling with a therapist |
Experimental: 2
During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add risperidone and behavioral family counseling to their treatment during Phase 2. If they do not respond to risperidone, they will switch to valproate.
|
Drug: Valproate
Standard therapeutic doses of valproate, set according to valproic acid blood level, for 8 weeks
Other Names:
Drug: Risperidone Standard therapeutic doses of risperidone for 8 weeks
Other Name: Risperdal Drug: Stimulant medication Stimulant medication standard in the care of ADHD, such as methylphenidate or dextroamphetamine
Other Names:
Behavioral: Behavioral family counseling Weekly behavioral counseling with a therapist |
Placebo Comparator: 3
During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add placebo and behavioral family counseling to their treatment during Phase 2.
|
Drug: Placebo
An inactive substance at identical dosing to active treatments for 8 weeks
Other Names:
Drug: Stimulant medication Stimulant medication standard in the care of ADHD, such as methylphenidate or dextroamphetamine
Other Names:
Behavioral: Behavioral family counseling Weekly behavioral counseling with a therapist |
- Aggressive behavior [ Time Frame: Measured weekly for 11 to 16 weeks ]
- ADHD symptoms [ Time Frame: Measured weekly for 11 to 16 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 6 Years to 12 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Presence of ADHD
- Presence of persistent, clinically significant aggression
- Presence of ODD or CD
Exclusion Criteria:
- Presence of psychosis
- Presence of a major developmental disability
- Presence of a major mood disorder
- Contraindications to stimulant, valproate, or risperidone treatment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00794625
Contact: Joseph C. Blader, PhD, MSc | 631-632-8317 | joseph.blader@stonybrook.edu | |
Contact: Lauren M. Chorney, PhD | 631-632-8317 | lauren.chorney@stonybrook.edu |
United States, New York | |
North Shore - LIJ Health System, Zucker Hillside Hospital | Recruiting |
Glen Oaks, New York, United States, 11040 | |
Contact: Ingrid S Fuentes, BA 718-470-8487 isfuentes@nshs.edu | |
Contact: Allison Berest, BA 718-470-8868 nkatsiot@nshs.edu | |
Principal Investigator: Vivian Kafantaris, MD | |
Stony Brook University Medical Center | Recruiting |
Stony Brook, New York, United States, 11794-8790 | |
Contact: Lauren M Chorney, PhD 631-632-8317 lauren.chorney@stonybrook.edu | |
Contact: Gabrielle A Carlson, MD (631) 632-8842 gabrielle.carlson@stonybrook.edu | |
Principal Investigator: Joseph C. Blader, PhD, MSc | |
United States, Texas | |
University of Texas Health Science Center at San Antonio | Recruiting |
San Antonio, Texas, United States, 78229 | |
Contact: Candy Rhine 210-614-7070 ext 250 rhine@uthscsa.edu | |
Contact: Maria Silva (210) 614-7070 ext 251 maria@cgcsanantonio.org | |
Principal Investigator: Steven Pliszka, MD | |
Sub-Investigator: Thomas L. Matthews, M.D. |
Principal Investigator: | Joseph C. Blader, PhD, MSc | Stony Brook University School of Medicine, State University of New York |
Responsible Party: | Joseph Blader, Associate Professor of Psychiatry, Stony Brook State University of New York, National Institute of Mental Health (NIMH) |
ClinicalTrials.gov Identifier: | NCT00794625 |
Other Study ID Numbers: |
R01MH080050 ( U.S. NIH Grant/Contract ) DSIR 84-CTM |
First Posted: | November 20, 2008 Key Record Dates |
Last Update Posted: | July 16, 2012 |
Last Verified: | July 2012 |
Attention-Deficit/Hyperactivity Disorder Aggressive Behavior Oppositional Defiant Disorder Conduct Disorder |
Hyperkinesis Disease Attention Deficit Disorder with Hyperactivity Aggression Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Behavioral Symptoms Valproic Acid Risperidone Dextroamphetamine |
Serotonin Antagonists Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Dopamine Antagonists Dopamine Agents Anticonvulsants Enzyme Inhibitors GABA Agents Antimanic Agents |